argenx NV ADR is a biotechnology business based in the US. argenx NV ADR shares (ARGX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $596.74 – an increase of 5.76% over the previous week. argenx NV ADR employs 1,148 staff and has a trailing 12-month revenue of around $1.9 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $596.74 |
|---|---|
| 52-week range | $327.73 - $611.22 |
| 50-day moving average | $550.08 |
| 200-day moving average | $450.86 |
| Wall St. target price | $602.51 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.78 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $591.82 from 2024-11-20
| 1 week (2024-11-15) | 4.89% |
|---|---|
| 1 month (2024-10-23) | 6.08% |
| 3 months (2024-08-22) | 13.89% |
| 6 months (2024-05-22) | 62.71% |
| 1 year (2023-11-22) | 20.29% |
|---|---|
| 2 years (2022-11-22) | 59.20% |
| 3 years (2021-11-22) | 117.33% |
| 5 years (2019-11-22) | 317.48% |
| Revenue TTM | $1.9 billion |
|---|---|
| Operating margin TTM | 2.75% |
| Gross profit TTM | $-251,786,000 |
| Return on assets TTM | -5.51% |
| Return on equity TTM | -5.74% |
| Profit margin | -2.11% |
| Book value | $71.28 |
| Market Capitalization | $35.8 billion |
TTM: trailing 12 months
We're not expecting argenx NV ADR to pay a dividend over the next 12 months.
Over the last 12 months, argenx NV ADR's shares have ranged in value from as little as $327.725 up to $611.223. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while argenx NV ADR's is 0.267. This would suggest that argenx NV ADR's shares are less volatile than average (for this exchange).
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S. À. R.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.